Advances in Targeting Signal Transduction Pathways
James A. McCubrey(East Carolina University), Zoya N. Demidenko(Roswell Park Comprehensive Cancer Center), William H. Chappell(University of North Carolina at Chapel Hill), Stephen L. Abrams(East Carolina University), Giovanni Ligresti(Boston University), Massimo Libra(University of Catania), Paolo Fagone(University of Catania), Lucio Cocco(University of Bologna), Camilla Evangelisti(University of Bologna), Michèle Milella(National Cancer Institute), Marco Donia(University of Copenhagen), Richard A. Franklin(Kamineni Institute of Dental Sciences), Antonio B. D’Assoro(Mayo Clinic), Alberto M. Martelli(University of Bologna), María Clorinda Mazzarino(University of Catania), Grazia Malaponte(University of Catania), Sanja Mijatović(University of Belgrade), Piotr Laidler(Jagiellonian University), Francesca Chiarini(University of Modena and Reggio Emilia), Л. Б. Дробот(Palladin Institute of Biochemistry), Kazuo Umezawa(Aichi Medical University), Melchiorre Cervello(Foundation for Biomedical Research), Saverio Candido(University of Catania), Giuseppe Montalto(University of Palermo), Joanna Dulińska-Litewka(Jagiellonian University), Jerry Polesel(Centro di Riferimento Oncologico), Danijela Maksimović‐Ivanić(Institute for Biological Research “Siniša Stanković”), Lin Sun(Shandong University), Ferdinando Nicoletti(University of Catania), Renato Talamini(Centro di Riferimento Oncologico), Agostino Tafuri(Azienda Ospedaliera Sant'Andrea), Linda S. Steelman(East Carolina University), Jörg Bäsecke(University of Göttingen)
Cited by 46
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25
|Nature|2008|1.3k
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
|Frontiers in Pharmacology|2018|878
Cancer Risk in the Swiss HIV Cohort Study: Associations With Immunodeficiency, Smoking, and Highly Active Antiretroviral Therapy
|JNCI Journal of the National Cancer Institute|2005|857